While most biotech startups chase the next billion-dollar blockbuster drug, Plexision is playing a different game entirely. With just 10 employees and a hyper-targeted focus on solid organ transplantation, this isn't a company looking to be the next Moderna—it's building an unassailable moat in personalized diagnostics.

"In a world of 'spray and pray' biotech, Plexision is doing the opposite: surgical precision in a $10B+ transplant market."

What makes Plexision unique isn't just their technology—it's their operational discipline. With a 10-person team generating $1.6M in revenue, that's $160K per employee. In biotech, where R&D burn rates typically dwarf revenue, this suggests either a highly efficient operation or a company in early commercialization phases. The lack of public funding data is telling—they're likely bootstrapped or privately held, avoiding the VC treadmill that forces premature scaling.

• Micro-team with macro-impact: 10 people serving a $10B+ transplant market
• Clinical-grade specificity: Keywords indicate deep domain expertise, not broad appeal
• Direct traffic dominance: 40% direct suggests strong referral networks and repeat usage
• Bootstrapped discipline: No public funding rounds visible—revenue-led growth